November 6th, 2014
Agent Could Potentially Reverse Anticoagulation Associated with Edoxaban
PER977 — a cation that binds to all of the new oral anticoagulants and heparin — may help reverse the anticoagulant effects of edoxaban, according to results of an industry-conducted trial published in the New England Journal of Medicine. Edoxaban, an oral factor Xa inhibitor, was recently recommended for approval by an FDA advisory panel.
Researchers studied whole-blood clotting time in 80 healthy people who were given PER977 following a dose of edoxaban. After receiving edoxaban, participants’ mean whole-blood clotting time rose by 37%. But after administration of PER977, whole-blood clotting time fell to within 10% of the baseline value in 10 minutes or less, and the effect lasted for 24 hours. Participants receiving placebo took 12 to 15 hours to reach that level.
The researchers did not observe signs of procoagulant activity with PER977, and adverse events were minimal.
This compound may also be effective and will likely be tested in the other new oral anticoagulants, as well as unfractionated heparin and low-molecular-weight heparins.